Fondazione Gimema Franco Mandelli Onlus

• Clinical trial investigating the efficacy of gilteritinib and chemotherapy treatment in patients with Acute myeloid leukemia Pending
  2024-518617-25-00 Phase II 1 country GILTERITINIB
• TALIM study, for the treatment of patients affected by persisent or recurrent Multiple Myeloma with the drug teclistamab and infusions of ly… Pending
  2025-521827-61-00 Phase II 1 country
• Study to treat adult patients with BCR-ABL1+ Chronic Myeloid Leukemia with Asciminib as single agent or in combination with nilotinib:a GIME… Recruiting
  2024-512696-12-00 Phase II 2 countries ASCIMINIB HYDROCHLORIDE; NILOTINIB
• Evaluaton of ibrutinib therapy for the treatment of autoimmune Hemolytic Anemia in Patients with Chronic Lymphocytic Leukemia/Small Lymphocy… Recruiting
  2023-509793-38-00 Phase II 1 country
• First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl-… Recruiting
  2023-510431-11-00 Phase II 1 country LAMIVUDINE; OBINUTUZUMAB; SULFAMETHOXAZOLE, TRIMETHOPRIM; ZANUBRUTINIB
• The study's aim is to treat adult patients affected by Ph-like ALL, a Philadelphianegative ALL subtype, with a combination of the tyrosine k… Recruiting
  2023-510240-20-00 Phase II 1 country PONATINIB
• The study is aimed at evaluating the feasibility of a hypomethylating treatment combined with hematopoietic stem cell transplantation in com… Recruiting
  2023-510515-19-00 Phase III 1 country AZACITIDINE
• Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting
  2023-510433-29-00 Phase III 1 country GEMTUZUMAB OZOGAMICIN
• Study to identify the most appropriate therapy for patients with Acute Myeloid Leukemia carrying FLT3 mutation, using the PBC biomarker to c… Recruiting
  2023-505901-17-00 Phase III 1 country CYTARABINE
• Trial aimed at examinate the functionality and effectiveness of the drug "IO" in adult patients with a rare form of cancer that affect the c… Recruiting
  2023-510516-39-00 Phase II 1 country INOTUZUMAB OZOGAMICIN; MERCAPTOPURINE
• Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL… Ended
  2024-511627-34-00 Phase II 1 country DARATUMUMAB
• Study aimed at evaluating the efficacy of the combination of the two drugs, Venetoclax and Azacitidine, on the treatment of patients sufferi… Ended
  2023-510432-36-00 Phase II 1 country
• Study aimed at evaluating the efficacy of a combination treatment (decitabine and venetoclax) in patients with Acute Myeliode Leukemia who a… Ended
  2023-510241-16-00 Phase II 1 country DECITABINE; VENETOCLAX
• The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended
  2023-508968-30-00 Phase III 1 country BLINATUMOMAB; CALCIUM LEVOFOLINATE; DEXAMETHASONE SODIUM PHOSPHATE; IDARUBICIN H…
• The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in pa… Ended
  2024-516868-28-00 Phase II 1 country PONATINIB
• Study to determine safety, efficacy and tolerability of Venetoclax in combination with Fludarabine, Citarabine and Idarubicin to achieve "th… Ended
  2023-510517-26-00 Phase I/II 1 country VENETOCLAX
• Sustained treatment-free period in the course of a disease when symptoms become less severe in BCR-ABL+ chronic myeloid leukemia: a prospect… Ended
  2023-510434-83-00 Phase IV 2 countries IMATINIB; NILOTINIB

Showing 1–17 of 17 trials